文献速递肿瘤 PET/CT骨显像与常规 SPECT核素与放射性配体治疗

双模态成像评估TH-302在实验性软骨肉瘤中的抗肿瘤疗效

Bimodality imaging as a companion to evaluate antitumour efficacy of TH-302 in experimental chondrosarcoma.
PubMed 文献 · EJNMMI Res · 2025-10-27

在大鼠软骨肉瘤模型中,采用核医学与MRI双模态成像评估缺氧激活前药TH-302对肿瘤微环境的疗效。TH-302使肿瘤体积减少75%,并改变肿瘤微结构、代谢及缺氧状态。多模态成像可监测治疗中肿瘤细胞与邻近微环境的复杂交互。

要点

  • TH-302在大鼠软骨肉瘤模型中显示抗肿瘤活性,肿瘤体积减少75%。
  • 双模态成像可无创监测TH-302对肿瘤代谢、缺氧及细胞外基质的影响。
  • 18F-FDG PET、18F-FMISO PET、99mTc-NTP 15-5 SPECT及CEST MRI联合评估肿瘤微环境变化。

核心结论

  • TH-302在软骨肉瘤体内模型中具有抗肿瘤活性,双模态成像可监测治疗中肿瘤细胞与邻近微环境的复杂交互。

研究设计与样本

  • 在大鼠软骨肉瘤模型上,对TH-302治疗组和对照组动物采用核医学与MRI双模态成像策略。

主要发现

  • TH-302使肿瘤体积在方案结束时减少75%,并改变肿瘤微结构、降低细胞密度和细胞增殖。
  • 18F-FDG PET和GLUT-1染色显示能量代谢改变,CEST-MRI和匹莫硝唑显示缺氧状态改变,99mTc-NTP 15-5 SPECT和sGAG检测显示蛋白聚糖改变。
  • 基因组分析显示与治疗相关的基因表达变化。

关键数值与推荐

  • T2和ADC通过MRI测量以监测肿瘤生长和结构。
  • 18F-FDG用于探索肿瘤代谢,18F-FMISO和APT to Guanidyl ratio CEST MRI评估缺氧状态。
  • 99mTc-NTP 15-5靶向蛋白聚糖,GAG CEST MRI探索细胞外基质蛋白聚糖。

临床怎么用

  • 双模态成像策略可用于临床前评估缺氧激活前药对软骨肉瘤微环境的疗效。

局限性

  • 研究仅在大鼠软骨肉瘤模型中进行,结论尚未在人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The hypoxic status of cancer tumour is disparate within tumour microenvironment and is considered as the main cause of treatment resistance. Chondrosarcoma, a type of bone cancer, combines heterogonous tumour microenvironment and resistance to therapies. We aimed to image tumour microenvironment response to hypoxia activated prodrug therapy with Evofosfamide (TH-302) on a rat chondrosarcoma model thanks to an original multimodal imaging strategy. Bimodal imaging strategy consisted of nuclear imaging and MRI on TH-302 treated and control animals. To monitor TH-302 effects on tumour growth and structure, we measured T2 and ADC by MRI and we used 18F-FDG to explore tumour metabolism. 18F-FMISO and APT to Guanidyl ratio CEST MRI evaluated hypoxic status. Proteoglycans in the extracellular matrix were explored in vivo by a radiotracer targeting proteoglycans (99mTc-NTP 15 - 5) and GAG CEST MRI. Immunohistochemistry, biochemical assays and RNA sequencing were performed to confirm in vivo observations. RESULTS: TH-302 demonstrated a strong efficacy on tumour structure with a reduction of its volume of 75% at the end of the protocol, a modification of the tumour microstructures and a decreased of both cellularity and cell proliferation. The drug also modified the tumour metabolisms as shown by 18F-FDG PET and GLUT-1 staining for the energetic one, CEST-MRI and pimonidazole for the hypoxic status and 99mTc-NTP 15 - 5 SPECT and sGAG assay for proteoglycans. Genomic analysis shown changes in gene expression related to therapy. CONCLUSIONS: TH-302 shows an in vivo anti-tumour activity in chondrosarcoma. Our multimodal imaging approach allows monitoring complex exchanges between tumour cells and their neighboring under therapy.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Autissier R, Pagés G, Boutault E, et al. Bimodality imaging as a companion to evaluate antitumour efficacy of TH-302 in experimental chondrosarcoma. EJNMMI Res. 2025. PMID: 41143943. doi:10.1186/s13550-025-01322-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。